Navigation Links
ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
Date:5/29/2009

EXTON, Pa., May 29 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) announced today that it will convene a meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology to discuss bioequivalence recommendations for oral vancomycin hydrochloride capsule drug products. The meeting is scheduled for August 4, 2009. FDA will make background material available to the public no later than two days before the meeting at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm.

Vancocin is the only approved product to treat Clostridium difficile-associated pseudomembranous colitis, one of the most common and devastating hospital-acquired infections. Clostridium difficile infection (CDI) can be severe, and without proper treatment, the associated complications of the disease can be deadly. The incidence of the disease observed in U.S. healthcare facilities more than doubled between 2000 and 2005; between 1999 and 2004, reported mortality rates from C. difficile in the U.S. more than quadrupled to 23.7 per million.

"ViroPharma views the convening of the advisory committee as a positive step towards open dialogue to discuss this very serious public health issue," commented Thomas Doyle, ViroPharma's vice-president, strategic initiatives. "ViroPharma will have an opportunity to address the Committee, and we look forward to what we hope will be a robust discussion of the many important issues raised by the Office of Generic Drugs' in vitro approach to bioequivalence for Vancocin."

About Clostridium difficile

One of the most serious problems facing the U.S. healthcare system today is hospital-acquired infections (HAIs). Clostridium difficile infection is one of the most common and devastating HAIs. The incidence of C. difficile observed in U.S. healthcare facilities more than doubled between 2000 and 2005; between 1999 and 2004, reported mortality rates from C. difficile in the U.S. more than quadrupled to 23.7 per million. Elderly patients exposed to antibiotics, long-term care patients, or those that have a serious underlying illness, are at greatest risk to contract the disease. Patients with this disease have GI tract conditions that are significantly different from those of a healthy individual due to infection. Typical symptoms include diarrhea, fever, nausea and abdominal pain and dehydration, though cases can lead to life threatening complications such as megacolon, peritonitis and perforation of the colon.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Certain statements in this press release may contain forward-looking statements that involve a number of risks and uncertainties including the Company's expectation that it will have an opportunity to address the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology and the expectation that a robust discussion of the OGD's in vitro approach to bioequivalence for Vancocin will occur. There can be no assurance that the FDA will continue with its stated plans regarding the subject matter of the Advisory Committee meeting, that the FDA will agree with the positions stated in ViroPharma's Vancocin related submissions or that ViroPharma's efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin through in vitro dissolution testing will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either ViroPharma's citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the FDA's December 2008 bioequivalence guidance for Vancocin, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancocin and our financial performance. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2009 could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma to Present at Two May Healthcare Conferences
2. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
3. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
4. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
5. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
6. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. ViroPharma Provides Update on Vancocin(R)
8. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
9. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
10. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
11. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... July 28, 2017 , ... ... of its budget on nutrition assistance programs. , Right now the most public ... . However, changes to other programs are under consideration, including WIC (Women, Infants, ...
(Date:7/28/2017)... ... July 28, 2017 , ... Kevin Harrington, one of the original Sharks from hit reality ... of a new DRTV campaign with My Real Earth. , Most people put their healthcare ... just as important as what we put in our bodies. After all, the skin is ...
(Date:7/28/2017)... OR (PRWEB) , ... July 28, 2017 , ... Date ... http://www.GlobalDragonTV.com , Like millions of first generation immigrants before her, Rose Hong ... beneficiary of generosity and sacrifice on the part of loving parents who made sure ...
(Date:7/28/2017)... ... 2017 , ... The DuPage County law firm of Mirabella Kincaid Frederick ... Ms. Cusack joins the team ready to provide clients with vigorous representation in ... in Peoria, Illinois, with a BA in Social Work. She earned her JD from ...
(Date:7/28/2017)... ... July 28, 2017 , ... As many parents, students, and teachers are getting ... sharpen mental acuity and address mental fatigue that can accompany long study hours, homework ... that can not only helps with school work but also in day-to-day functions on ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/28/2017)... , July 28, 2017 EnvoyHealth, a Diplomat company, ... a program for CleverCap LITE, a technology designed to ... to deliver innovative health technology solutions and services that ... CleverCap LITE offers medication monitoring ... bottle cover: Records ...
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
Breaking Medicine Technology: